शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSEOXYGENTA PHARMACEUTICAL LIMITE· Pharmaceuticals & BiotechnologyMinimalNeutral
Announced Tue, 13 Oct, 2026 · 14:59 IST

Routine SEBI dematerialisation compliance certificate for Sep 2026 quarter

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-2.5%Reaction day
₹48.50
prior close
₹46.60
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-2.7% vs market
Pharmaceuticals peers, median of 168sector-0.3%-2.2% vs sector

On the reaction day the stock moved 2.7 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
+1.5
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-2.5+0.2-2.7-0.3-2.2
Next day
-2.9+0.9-3.8-0.3-2.6
2d
-3.1-0.8-2.3-1.2-1.9
3d
-3.1-0.1-3.0-1.0-2.1
4d
-3.9-1.7-2.2-2.6-1.3
5d
-2.7-4.3+1.6-4.0+1.3
1w
-5.0-7.5+2.5-6.5+1.5
15d
-3.1-3.6+0.5-1.4-1.7
1m
—————
2m
—————
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 168Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Oxygenta Pharmaceutical has submitted a routine compliance certificate under SEBI Regulation 74(5) for the quarter ended 30 September 2026. The company's Registrar and Transfer Agent, Venture Capital and Corporate Investments, confirmed that all share certificates received for dematerialisation were properly cancelled and the company records were updated with NSDL and CDSL as registered owner within 15 days. This is a standard quarterly procedural filing required by SEBI.

Likely market impact

No material impact on shareholders. This is a routine regulatory compliance filing with no bearing on operations, financials, or share price.